Section 3(d) Archives - GIP Research & Consultancy Services

Patent granted in India to CENTER OF INNOVATIVE AND APPLIED BIOPROCESSING

December 14, 2021

Patent number 366820 has been granted to CENTER OF INNOVATIVE AND APPLIED BIOPROCESSING that is titled A PROCESS FOR THE PRODUCTION OF PREBIOTIC OLIGOSACCHARIDES AND NEARLY ZERO CALORIE FUNCTIONAL SUGAR FROM CANE MOLASSES, AND USES OF THE SAME. The present invention discloses a significant enhancement in the known efficacy of the cane industry waste or by-product, cane molasses, by producing high-value biomolecules of reduced calorie, prebiotic and other functional properties of health benefits. The cane industry waste or by-product, cane molasses, does not have any known properties of prebiotic oligosaccharides, and D-allulose (or D-psicose). This patent falls under the category of Biotechnology. Overall, this patent covers a process involving the agro-industrial by-products of the sugar cane industry raw molasses, acceptor molecules extracted from starch industry residue, and the catalytic proteins with dextransucrase and D-psicose 3-epimerase activities as the key ingredients to produce high value non-digestible oligosaccharides and functional monosaccharide sugar- D-psicose.

Patent granted in India to UNIVERSITY OF CANBERRA

patent number 381277 has been granted to the UNIVERSITY OF CANBERRA titled COMPOSITIONS FOR MODULATING CANCER STEM CELLS AND USES THEREFOR. The patent applicant responded to this objection by stating that the claimed compound does not pertain to mere forms/derivatives of known compounds. Therefore, the present invention does not fall under section 3(d) of the Patents Act. This patent falls under the category of Pharmaceuticals. Overall, this patent covers composition and methods for modulating cancer stem cells. More particularly, the present invention discloses the use of lysine demethylase (LSD) inhibitors and protein kinase C theta inhibitors (PKC-θ) for inhibiting the growth of LSD- and/or PKC-θ-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including non-metastatic and metastatic cancer and/or for preventing cancer recurrence.

Patent granted in India to JINA PHARMACEUTICALS, INC.

December 13, 2021

Patent number 381262 has been granted to JINA PHARMACEUTICALS, INC. that is titled IMPROVED PHARMACEUTICAL COMPOSITION OF ENDOXIFEN & PREPARATION THEREOF. The patent applicant responded to this objection by stating that the claimed compound does not pertain to mere forms/derivatives of known compounds. This patent falls under the category of Pharmaceuticals. Overall, this patent covers a pharmaceutical composition comprising a core, wherein said core comprises endoxifen or pharmaceutically acceptable salt thereof, a sub-coat surrounding the core, an enteric coat surrounding the sub-coat and optionally a color coat surrounding the enteric coat.

Patent granted in India to SABIC GLOBAL TECHNOLOGIES B.V.

October 25, 2021

Patent number 378988 has been granted to SABIC GLOBAL TECHNOLOGIES B.V. that is titled CATALYST COMPOSITION FOR THE POLYMERIZATION OF OLEFINS. The patent applicant responded to this objection by stating that the claimed invention does not pertain to mere forms/derivatives of known compounds. The applicant further submits that the present set of claims are novel and inventive over the features described under prior arts and that neither documents specifically described the process as used in the present invention. This patent falls under the category of Polymer Technology. Overall, this patent covers a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, one histone stem-loop and a poly(A) sequence or a polyadenylation signal.

Patent granted in India to SIMMONS William H.

Patent number 378938 has been granted to SIMMONS William H. that is titled 4 FLUORO THIO CONTAINING INHIBITORS OF APP2 COMPOSITIONS THEREOF AND METHOD OF USE. The patent applicant responded to this objection by stating that the claimed compound does not pertain to mere forms/derivatives of known compounds. This patent falls under the category of Chemical. Overall, this patent covers a fluoro-thiol-containing compound that is capable of specifically inhibiting the enzyme, membrane-bound aminopeptidase P2 5 (APP2), whose natural substrate is bradykinin. The compound is useful as a pharmaceutical agent because by inhibiting bradykinin degradation, the compound allows endogenous bradykinin to exert its beneficial effects in the body including dilating coronary arteries, providing protective effects in the heart during myocardial ischemia/reperfusion injury, stimulating formation of new blood vessels, improving organ 10 function in chronic heart and renal disease, and improving glucose tolerance and insulin sensitivity.

Patent granted in India to ARYSTA LIFESCIENCE NORTH AMERICA LLC

October 11, 2021

Patent number 378319 has been granted to ARYSTA LIFESCIENCE NORTH AMERICA LLC that is titled SURFACTANT STABILIZED CYCLOHEXENE DIOXIDE OXIME FORMULATIONS. The primary independent claim of this patent states a composition comprising a cyclohexanedione oxime or an agriculturally acceptable salt thereof and one stabilizing surfactant to provide a stabilized cyclohexanedione oxime. The patent applicant responded to this objection by stating that the original claims have been deleted as directed by the Controller and requested for the withdrawal of the objection. This patent falls under the category of Chemical. Overall, this patent covers herbicidal formulations including a combination of an active herbicide, in particular, a cyclohexanedione oxime herbicide, and a stabilizing surfactant. The herbicidal formulations, for example, have improved storage stability.

Patent granted in India to MERZ PHARMA GMBH & CO. KGAA.

Patent number 378301 has been granted to MERZ PHARMA GMBH & CO. KGAA that is titled PROCESS FOR PREPARING A HIGHLY PURE NEUROTOXIC COMPONENT OF A BOTULINUM TOXIN AND USES THEREOF. The primary independent claim of this patent states a process for preparing a highly pure neurotoxic component of a botulinum toxin. The method includes cultivation of Clostridium Botulinum under conditions that allow production of a botulinum toxin. The patent applicant responded to this objection by stating that the claimed process does not pertain to mere forms/derivatives of known compounds. The applicant further submits that the examples provided in the filed specification show the enhanced efficacy of the claimed highly pure neurotoxic component. This patent falls under the category of Chemical. Overall, this patent covers a process for preparing a highly pure neurotoxic component of a botulinum toxin by cultivating Clostridium botulinum under conditions that allow production of a botulinum toxin, and isolating the neurotoxic component from the botulinum toxin.

Patent granted in India to NALCO COMPANY

September 18, 2021

Patent number 376406 has been granted to NALCO COMPANY that is titled CHEMICAL TREATMENT TO IMPROVE RED MUD SEPARATION AND WASHING IN THE BAYER PROCESS. The patent applicant responded to this objection by stating that the claimed process for preparing a composition defines novel and non-obvious technical features and therefore cannot be considered as a mere use of a “known” process as disclosed in the cited references. Therefore, the present invention does not fall under section 3(d) of the Patents Act. This patent falls under the category of Chemical. Overall, this patent covers an invention that provides methods and compositions for improving the rheology of red mud removed from Bayer Process liquor.

Patent granted in India to CONSTELLATION PHARMACEUTICALS, INC.

Patent number 376397 has been granted to CONSTELLATION PHARMACEUTICALS, INC. that is titled LSD1 INHIBITORS AND MEDICAL USES THEREOF. The patent applicant responded to this objection by stating that the claimed process for preparing a composition defines novel and non-obvious technical features and therefore cannot be considered as a mere use of a “known” process as disclosed in the cited references. This patent falls under the category of Chemical. Overall, this patent covers novel compounds of Formula (I or Ia’) and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1.

Patent granted in India to BAYER PHARMA AKTIENGESELLSCHAFT

September 4, 2021

patent number 375367 has been granted to BAYER PHARMA AKTIENGESELLSCHAFT that is titled ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDLE PROTEIN (KSP). The patent applicant responded to this objection by stating that the cited compounds are pyrazole derivatives or pyrrole derivatives. The claimed invention indicates the cytotoxic effects of claimed drug conjugates demonstrating the cytotoxicity in various cell lines, including human lung carcinoma cells, human pancreas carcinoma cells, and human breast carcinoma cells. This patent falls under the category of Chemical. Overall, this patent covers a conjugate of a binder or derivative thereof with one or more active compound molecules, the active compound molecule being a kinesin spindle protein inhibitor attached to the binder via a linker L.

GIP Research & Consultancy Services

Tag: Section 3(d)